FIM
CPRX

Freedom Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Freedom Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,604
Closed -$257K – 745
2025
Q1 		$257K Sell
10,604
-2,106
-17% -$47.4K 0.02% 643
2024
Q4 		$265K Sell
12,710
-3,200
-20% -$68.7K 0.02% 638
2024
Q3 		$316K Sell
15,910
-3,223
-17% -$59.7K 0.03% 582
2024
Q2 		$296K Buy
19,133
+1,685
+10% +$26.2K 0.02% 605
2024
Q1 		$278K Buy
+17,448
New +$263K 0.02% 635
2023
Q3 		– Sell
-17,941
Closed -$241K – 696
2023
Q2 		$241K Sell
17,941
-1,629
-8% -$23.4K 0.03% 606
2023
Q1 		$324K Sell
19,570
-1,233
-6% -$20.3K 0.04% 528
2022
Q4 		$387K Buy
20,803
+323
+2% +$4.97K 0.04% 505
2022
Q3 		$263K Buy
20,480
+1,579
+8% +$18.7K 0.03% 597
2022
Q2 		$132K Buy
+18,901
New +$139K 0.01% 691

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Freedom Investment Management's CPRX Position: Q2 2025 in Review

Freedom Investment Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 10,604 shares — an estimated $257K sold.

Freedom Investment Management first reported a position in CPRX in Q2 2022 and held it in 10 quarters. The position peaked at $387K in Q4 2022. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

  • Freedom Investment Management reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Freedom Investment Management sold 10,604 Catalyst Pharmaceutical shares in Q2 2025, an estimated $257K.
  • Freedom Investment Management first reported a position in Catalyst Pharmaceutical in Q2 2022 and held it in 10 quarters.
  • Freedom Investment Management's Catalyst Pharmaceutical position peaked at $387K in Q4 2022.
  • 365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on Freedom Investment Management's 13F filing for Q2 2025, filed 30 Jul 2025.